528 related articles for article (PubMed ID: 20153427)
1. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
[TBL] [Abstract][Full Text] [Related]
2. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
3. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
5. Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines.
Reichrath S; Müller CS; Gleissner B; Pfreundschuh M; Vogt T; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):420-4. PubMed ID: 20206691
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
[TBL] [Abstract][Full Text] [Related]
8. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
9. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification.
Fu B; Wang H; Wang J; Barouhas I; Liu W; Shuboy A; Bushinsky DA; Zhou D; Favus MJ
PLoS One; 2013; 8(4):e61423. PubMed ID: 23620751
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
13. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
14. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro.
Seifert M; Rech M; Meineke V; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):375-9. PubMed ID: 15225804
[TBL] [Abstract][Full Text] [Related]
15. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells.
Pramanik R; Asplin JR; Lindeman C; Favus MJ; Bai S; Coe FL
Cell Immunol; 2004; 232(1-2):137-43. PubMed ID: 15876428
[TBL] [Abstract][Full Text] [Related]
16. Mineralization of three-dimensional osteoblast cultures is enhanced by the interaction of 1α,25-dihydroxyvitamin D3 and BMP2 via two specific vitamin D receptors.
Chen J; Dosier CR; Park JH; De S; Guldberg RE; Boyan BD; Schwartz Z
J Tissue Eng Regen Med; 2016 Jan; 10(1):40-51. PubMed ID: 23784946
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
18. The effects of 1alpha,25-dihydroxyvitamin D3 on the expression of DNA replication genes.
Eelen G; Verlinden L; van Camp M; van Hummelen P; Marchal K; de Moor B; Mathieu C; Carmeliet G; Bouillon R; Verstuyf A
J Bone Miner Res; 2004 Jan; 19(1):133-46. PubMed ID: 14753745
[TBL] [Abstract][Full Text] [Related]
19. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
20. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]